Leukemia

Leukemia remission rates increased after induction therapy of homoharringtonine with cytarabine and aclarubicin

Published in Blood Weekly, September 28th, 2006

Patients with de novo acute myeloid leukemia (AML) experienced high complete remission (CR) rates after their first induction therapy with homoharringtonine in combination with cytarabine and aclarubicin (HAA).

According to a recent report published in the journal Leukemia, researchers in People's Republic of China conducted a study "to assess the efficacy and toxicity of HAA regimen (homoharritonine 4mg/m²/day, days 1-3; cytarabine 150mg/m²/day, days 1-7; aclarubicin 12 mg/m²/day, days 1-7) as an induction therapy in the treatment of AML, 48 patients with newly diagnosed AML, aged 35 (14-57) years, were entered into this clinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2006-09-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry